The DOI matches its Crossref record.
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.
Abstract
PURPOSE: To describe the occurrence of secondary acute myeloid leukemia (AML) in children with acute lymphoblastic leukemia (ALL) treated with etoposide (VP-16). PATIENTS AND METHODS: Two hundred five consecutive children with early B-lineage ALL were treated according to the Dallas/Fort Worth (DFW) protocol between January 1986 and July 1, 1991. Therapy included a four-drug induction followed by consolidation and continuation phases of nightly oral mercaptopurine (6-MP) and repetitive courses of divided-dose oral methotrexate (dMTX) and asparaginase (L-asp). Three doses of VP-16 and cytarabine (Ara-C) were given during consolidation and later, during continuation, two doses were given 3 to 4 days apart, every 9 weeks. Intrathecal (IT) chemotherapy was given throughout the treatment period. RESULTS: Two hundred three of the 205 patients entered remission. Only eight of these 203 children have had a bone marrow relapse (ALL). However, 10 other children have developed secondary AML 23 to 68 months following the diagnosis of ALL. Overall event-free survival (EFS) at 4 years is 79.3% +/- 5.1%, with a risk of secondary AML at 4 years of 5.9% +/- 3.2%. CONCLUSION: This experience provides strong evidence for a link between epipodophyllotoxin therapy and secondary AML since none of these children received alkylating agent therapy or irradiation. This serious complication raises concern as to the appropriate use of epipodophyllotoxins in the treatment of childhood ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma
Murphree, A. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140548005 · Cited by 468
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 418
Oeffinger, K. C., & Hudson, M. M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.4.208 · Cited by 365
Darrington, D. L., Vose, J. M., Anderson, J. R., Bierman, P. J., Bishop, M. R., Chan, W. C., Morris, M. E., Reed, E. C., Sanger, W. G., & Tarantolo, S. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2527 · Cited by 332
Metadata
- Authors
- Winick, N. J., McKenna, R. W., Shuster, J. J., Schneider, N. R., Borowitz, M. J., Bowman, W. P., Jacaruso, D., Kamen, B. A., & Buchanan, G. R.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-02
- Volume
- 11
- Issue
- 2
- Pages
- 209-217
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2242925189
- Cited by
- 267
- References
- 0
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. https://app.cochat.ai/papers/10.1200/jco.1993.11.2.209
- The paper
- Winick, N. J., McKenna, R. W., Shuster, J. J., Schneider, N. R., Borowitz, M. J., Bowman, W. P., Jacaruso, D., Kamen, B. A., & Buchanan, G. R. (1993). Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.2.209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.